RecruitingNCT06725940

GzmB-PET/CT to Evaluate Neoadjuvant Therapy Efficacy in Breast Cancer

Clinical Study on the Evaluation of Neoadjuvant Therapy Efficacy in Breast Cancer Using PET/CT With Granzyme B Imaging Probe

Sponsor

Shanghai Jiao Tong University School of Medicine

Enrollment

50 participants

Start Date

Nov 1, 2024

Study Type

OBSERVATIONAL

Conditions

Breast Cancer Invasive

Summary

To explore the efficacy of 68Ga-GZMB PET/CT in assessing the response to neoadjuvant therapy for breast cancer, and to investigate the optimal SUVmax threshold of 68Ga-GZMB PET/CT for predicting pathological complete response (pCR), aiming to provide a new and effective means for accurately and non-invasively evaluating the efficacy of neoadjuvant therapy.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new imaging scan using a radioactive tracer that targets granzyme B — a protein released when immune cells attack cancer — to monitor how well neoadjuvant (pre-surgery) therapy is working in breast cancer patients. **You may be eligible if...** - Age 16–65 - Have confirmed primary invasive breast cancer on one side - Tumor is at least 2 cm, with positive lymph nodes, and you are scheduled to receive pre-surgery (neoadjuvant) treatment - Have complete clinical and tissue testing records - ECOG performance status 0–1 (able to carry out normal activities) **You may NOT be eligible if...** - Are pregnant or breastfeeding - Have had prior breast cancer surgery - Have bilateral (both sides) breast cancer - Are unable to undergo PET/CT imaging Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.